VivoSeq
Infectious Disease

Helicobacter Pylori Eradication

0

Pipeline Programs

14

Active Trials

3

Companies Involved

Helicobacter Pylori Eradication is an early-stage landscape with 0 programs across 3 companies. The most active players are Hangzhou Grand Biologic Pharmaceutical, Inc., Takeda, TenNor Therapeutics (Suzhou) Limited.

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

1/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

76

clinical trials

Completed47 · 62%
Unknown status13 · 17%
Recruiting9 · 12%
Not yet recruiting4 · 5%
Enrolling by invitation1 · 1%
Suspended1 · 1%
Other1 · 1%

Trial Activity

76 trials

Helicobacter Pylori Eradication and Follow-up
Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT05061732·4,447 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)